Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 11—November 2002
THEME ISSUE
Tuberculosis Genotyping
Tuberculosis Genotyping Network, United States

Molecular Epidemiology of Multidrug-Resistant Tuberculosis, New York City, 1995–1997

Sonal S. Munsiff*†Comments to Author , Trina Bassoff*, Beth Nivin*, Jiehui Li*, Anu Sharma*, Pablo Bifani‡, Barun Mathema‡, Jeffrey Driscoll§, and Barry N. Kreiswirth‡
Author affiliations: *New York City Department of Health, New York, New York, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Public Health Research Institute TB Center, Newark, New Jersey, USA; §Wadsworth Center, Albany, New York, USA;

Main Article

Table 3

Risk factors associated with clustering of multidrug-resistant tuberculosis cases, New York City, 1995–1997 (n=234)

Characteristic Clustered (n=153) No. (%) Nonclustered (n-81) No. (%) Crude OR 95% CI
Median age in yr (range) 41 (5–85) 42 (22–77) 0.99 0.98, 1.02
Male sex 93 (60.8) 49 (60.5) 1.01 0.58, 1.76
U.S.-born 120 (79.0) 42 (51.9) 3.48 1.94, 6.25
Median years of residence in United Statesb 12 (0–47) 6.5 (0–24) 1.09 1.02, 1.16
HIV serostatus
Positive 96 (62.8) 29 (35.8) 2.81 1.52, 5.22
Negative 40 (26.1) 34 (42.0) 1.00
Unknown 17 (11.1) 18 (22.2) 0.80 0.36, 1.80
Race/ethnicity
Asian 6 (3.9) 16 (19.8) 0.18 0.06, 0.53
Hispanic 49 (32.0) 24 (29.6) 1.00
Black non-Hispanic 72 (47.1) 31 (38.3) 1.14 0.60, 2.17
White non-Hispanic 26 (17.0) 10 (12.4) 1.27 0.53, 3.06
Health-care worker 12 (7.8) 2 (2.5) 3.36 0.73, 15.40
Homeless 22 (14.4) 5 (6.2) 2.55 0.92, 7.02
Injection drug usec 24 (15.7) 8 (9.9) 1.70 0.73, 3.97
Prior treatment history 10 (6.5) 12 (14.8) 0.40 0.17, 0.98
Having epidemiologic linkd
Nosocomial 7 (4.6) 0 (0) 2.97 1.02, 9.26
Community 18 (11.8) 5 (11.1)
No link 128 (83.7) 76 (88.9) 1.00
Year of diagnosis
1995 69 (45.1) 32 (39.5) 1.00
1996 54 (35.3) 27 (33.3) 0.93 0.47, 1.81
1997 30 (19.6) 22 (27.2) 0.63 0.30, 1.34

aOR, odds ratio; CI, confidence interval.
bExcludes non-U.S.-born patients.
cInjection drug use within 12 months before diagnosis.
dCompared epidemiologic link with no epidemiologic link

Main Article

Page created: July 19, 2010
Page updated: July 19, 2010
Page reviewed: July 19, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external